SBIR/STTR Research Award

" Channel Multimodal Ultrathin Flexible SFE for cancer diagnosis and therapy"

Award identifier a4816eb05ed6771c4515d48844f7425b45d9fe1420fed847b0b0d627bb0a2100Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$300,000

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
VERAVANTI INC.
Proposal award date
2017-05-15
Contract end date
2018-07-31
UEI
QCKNV6BL8B23
Solicitation number
PA16-302
Topic code
102

Research abstract

Summary channel multimodal ultrathin flexible SFE for cancer diagnosis and therapy Minimally invasive optical imaging is being advanced by molecular probes that enhance contrast using fluorescence The applications in cancer imaging are very broad ranging from early diagnosis of cancer to the guiding of interventions such as surgery The high sensitivity afforded by wide field fluorescence imaging using scanning laser light is being developed for these broad applications The platform technology is the SFE Scanning Fiber Endoscope which places a sub mm scanner at the tip of a highly flexible scope Because several different laser wavelengths can be mixed and scanned together full color reflectance imaging can be combined with fluorescence imaging in a channel multimodal SFE The goal of this project is to develop the first prototype VerAvanti channel multimodal SFE mmSFE for cancer imaging applications VerAvanti is a start up medical device company located in Redmond WA founded and staffed with engineering graduates from the University of Washington UW where the SFE was invented and tested in pilot clinical trials VerAvanti has exclusive license to commercialize the SFE technology for medical imaging and a channel full color SFE using red green and blue reflectance is already in pilot manufacturing and testing This project will rapidly translate the mmSFE technology from its origins at UW into a working prototype by adding near infrared NIR fluorescence as the th imaging channel Importantly the VerAvanti mmSFE will be designed for efficient manufacturing in a modular format with reduced part numbers This will allow two very different cancer imaging applications to be commercially available for upcoming clinical trials that rely on molecular imaging of cancer The first application is fluorescence image guided surgery specifically brain tumors that are labeled with BLZ a peptide probe with a NIR dye to highlight cancer cells especially at the margin with healthy brain tissue The ultrathin and flexible mmSFE will allow less invasive surgeries and allow the guided tool to avoid the most important areas to be left intact VerAvanti will design and develop the prototype to specified benchmarks which will be tested at UW using realistic phantoms and feedback from clinicians The challenge for VerAvanti is extending from to laser wavelengths across the visible to NIR with a clinical interface that neurosurgeons prefer The second application is providing fluorescence imaging channels concurrently with grayscale reflectance imaging for the purpose of making an accurate cancer diagnosis in the pancreatobiliary ducts that are often too small to obtain sufficient biopsy tissue Feasibility of the modular mmSFE design using to fluorescence imaging channels and reflectance for situational awareness in a mm diameter flexible scope will be determined but only the mmSFE for the first application will be prototyped and neurosurgeon tested Project Narrative This SFE endoscope technology was developed by the University of Washington and licensed to VerAvanti for rapidly bringing to the clinic as a commercial product This project in collaboration with the University of Washington inventors will demonstrate the technical feasibility that this multimodal imaging technology offers in more accurately guiding cancer diagnosis and surgically removing tumors

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2017–2024). Reported award amounts total $2,890,865. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.